[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100609751":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":41,"centralContacts":46,"locations":53,"responsibleParty":67,"collaborators":69,"id":73,"slug":74,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":51,"eligibilityCriteria":78,"healthyVolunteers":79,"sex":80,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":51,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":91,"overallStatus":96,"whyStopped":51,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"University of Wisconsin, Madison","OTHER",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"Healthy controls","EXPERIMENTAL","Male and female participants 18-45 without Metabolic Syndrome. On study for 3 visits (up to 6 months). Randomized to either Placebo then Indomethacin or Indomethacin then Placebo for 2 MRI visits.",[13,14,15],"Drug: Indomethacin","Drug: Placebo","Diagnostic Test: MRI",{"label":17,"type":10,"description":18,"interventionNames":19},"Metabolic Syndrome","Male and female participants, age-matched with Healthy Controls, who have at least 3 defining symptoms of Metabolic Syndrome. Randomized to either Placebo then Indomethacin or Indomethacin then Placebo for 2 MRI visits.",[13,14,15],[21,28,34],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Indomethacin","Indomethacin is a nonsteroidal anti-inflammatory. It prevents the production of prostaglandins, endogenous signaling molecules known to cause symptoms from inflammation.\n\nIndomethacin (1.5 mg\u002Fkg) will be taken orally prior to one MRI study visit.",[9,17],[27],"Indo",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Placebo","Participants will be screened for lactose intolerance. Total dosing will be calculated to match the mg needed for the indomethacin study visit.",[9,17],[33],"Lactose",{"type":35,"name":36,"description":37,"armGroupLabels":38,"otherNames":39},"DIAGNOSTIC_TEST","MRI","CBF testing will be performed on 3T MRI scanners (GE Healthcare)",[9,17],[40],"Magnetic Resonance Imaging",[42],{"name":43,"affiliation":44,"role":45},"William Schrage, PhD","UW Madison","PRINCIPAL_INVESTIGATOR",[47],{"name":48,"role":49,"phone":50,"phoneExt":51,"email":52},"Shawn Bolin, MS","CONTACT","608-263-6308",null,"sbolin@wisc.edu",[54],{"facility":55,"status":51,"city":56,"state":57,"zip":58,"country":59,"countryCode":60,"cosmosGeoPoint":61,"geoPoint":66,"contacts":51},"University of Wisconsin","Madison","Wisconsin","53706","United States","US",{"type":62,"coordinates":63},"Point",[64,65],-89.40123,43.07305,{"lat":65,"lon":64},{"type":68,"investigatorFullName":51,"investigatorTitle":51,"investigatorAffiliation":51,"oldNameTitle":51,"oldOrganization":51},"SPONSOR",[70],{"name":71,"class":72},"National Institutes of Health (NIH)","NIH","100609751","early-phase-1-human-cerebrovascular-blood-flow-and-sex-differences-in-metabolic-syndrome-100609751",false,"NCT07218653","Human Cerebrovascular Blood Flow and Sex Differences in Metabolic Syndrome","Inclusion Criteria (Healthy Controls):\n\n* 18-45 years old\n* Normal fasting values for blood glucose (less than 100 g\u002Fdl)\n* Normal values for lipids (LDL cholesterol less than 130 mg\u002Fdl, triglycerides less than 150 mg\u002Fdl) and HDL (men greater than 40, women greater than 50 mg\u002Fdl)\n* Women must have a predictable menstrual cycle. Females will be studied on cycle days 1-7 to minimize sex hormone differences and their potential confounding effects on vascular outcomes. Oral contraceptives are allowed, and women will be studied during their placebo phase.\n\nInclusion Criteria (Participants with Metabolic Syndrome):\n\n* 18-45 years old\n* Meet at least 3 of the 5 ATP MetSyn criteria. These are:\n\n  1. Waist circumference greater than 102 cm (males) or 82 cm (females)\n  2. Triglycerides greater than 150 mg\u002FdL\n  3. HDL cholesterol less than 40 mg\u002FdL (males) or 50 mg\u002FdL (females)\n  4. Blood pressure greater than or equal to 130\u002F85 mmHg\n  5. Fasting plasma glucose greater than 110 mg\u002FdL\n\nExclusion Criteria (Healthy Controls):\n\n* Body Mass Index (BMI) greater than or equal to 25 kg\u002Fm2\n* Blood pressure over 130\u002F80 mmHg\n* Meeting any of the 5 MetSyn criteria listed above.\n\nExclusion Criteria (all participants):\n\n* Current smoker, defined as more than 5 cigarettes over past 30 days\n* Current diagnosis or history of:\n\n  * peripheral vascular disease\n  * hepatic disease\n  * renal disease\n  * lung disease\n  * gastrointestinal disorders\u002Fbleeding\n  * hematologic disease\n  * stroke\n  * myocardial infarction\n  * coronary heart disease\n  * congestive heart failure\n  * heart surgery\n  * sleep apnea\n  * autoimmune diseases\n  * HIV\n  * traumatic brain injury, concussion, stroke, or seizures\n  * Asthma\n  * Polycystic ovarian syndrome\n  * Type II diabetes\n  * Currently pregnant or breastfeeding\n  * Current musculoskeletal injury\n  * Medication use known to influence cardiovascular function, other than contraceptive hormones. Broadly, the classes of drugs relate to treating blood pressure, diabetes, cholesterol.\n  * Claustrophobia\n* Lactose intolerance\n* Magnesium-restricted diet",true,"ALL","18 Years","45 Years",{"count":84,"type":85},72,"ESTIMATED","INTERVENTIONAL",[88],"EARLY_PHASE1","This study tests the hypothesis that Metabolic Syndrome (MetSyn) decreases cerebral blood flow (CBF) more in females than males due in part to the sex-specific loss of COX vasodilation. Male and female participants will be enrolled in two groups: Health Controls versus participants with MetSyn.",[17],[92,93,94,17,95],"Cerebral Blood Flow","CBF","COX","MetSyn","NOT_YET_RECRUITING","2026-05-20",{"date":99,"type":100},"2026-05-26","ACTUAL",{"date":102,"type":85},"2026-07",{"date":104,"type":85},"2031-07",{"name":5,"class":6},1]